Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
复制标题
DOI：
10.1073/pnas.93.21.11341
复制
发表时间：
1996-10-15
影响因子：
11.1
通讯作者：
Moss, B
中科院分区：
文献类型：
--
作者：
Moss, B
牛痘病毒，不再需要免疫天花，现在作为一个独特的载体表达基因的细胞质内的哺乳动物细胞。作为一种研究工具，重组牛痘病毒用于合成和分析蛋白质的结构-功能关系，确定体液和细胞介导的免疫的靶点，并研究保护免受特定传染病和癌症所需的免疫应答类型。重组牛痘病毒的疫苗潜力已经以有效的口服野生狂犬病疫苗的形式实现，尽管还没有人用产品获得许可。不能在哺乳动物细胞中复制并产生减少的细胞病变效应的基因改变的牛痘病毒保留了高水平基因表达和免疫原性的能力，同时对实验室工作人员和潜在的疫苗接受者具有特殊的安全性。
Vaccinia virus, no longer required for immunization against smallpox, now serves as a unique vector for expressing genes within the cytoplasm of mammalian cells. As a research tool, recombinant vaccinia viruses are used to synthesize and analyze the structure-function relationships of proteins, determine the targets of humoral and cell-mediated immunity, and investigate the types of immune response needed for protection against specific;infectious diseases and cancer. The vaccine potential of recombinant vaccinia virus has been realized in the form of an effective oral wild-life rabies vaccine, although no product for humans has been licensed. A genetically altered vaccinia virus that is unable to replicate in mammalian cells and produces diminished cytopathic effects retains the capacity for high-level gene expression and immunogenicity while promising exceptional safety for laboratory workers and potential vaccine recipients.